We are live on
!
Find out more
PCM
Piermont Capital Management Portfolio holdings
AUM
$211M
1-Year Est. Return
8.09%
This Fund
S&P 500
This Quarter
Est. Return
+6.94%
1 Year Est. Return
-8.09%
3 Year Est. Return
+33.18%
5 Year Est. Return
+53.13%
10 Year Est. Return
–
AUM
$302M
AUM Growth
-$47.7M
(-14%)
Cap. Flow
-$64.2M
Cap. Flow
% of AUM
-21.27%
Top 10 Holdings %
Top 10 Hldgs %
11.03%
Holding
289
New
44
Increased
30
Reduced
124
Closed
47
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DF
Dean Foods Company
DF
|
+$2.9M |
| 2 |
Old National Bancorp
ONB
|
+$2.33M |
| 3 |
GOOD
Gladstone Commercial Corp
GOOD
|
+$2.3M |
| 4 |
Wintrust Financial
WTFC
|
+$2.28M |
| 5 |
The Greenbrier Companies
GBX
|
+$2.27M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Interface
TILE
|
+$2.96M |
| 2 |
Avista
AVA
|
+$2.75M |
| 3 |
First American
FAF
|
+$2.71M |
| 4 |
DCT
DCT Industrial Trust Inc.
DCT
|
+$2.6M |
| 5 |
Associated Banc-Corp
ASB
|
+$2.57M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 23.79% |
| 2 | Industrials | 16.43% |
| 3 | Technology | 11.46% |
| 4 | Real Estate | 10.44% |
| 5 | Consumer Discretionary | 9.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Piper Sandler
PIPR
$5.26B
| $265K | 0.09% |
+17,840
| New | +$263K |
|
227
CytomX Therapeutics
CTMX
$734M
| $262K | 0.09% |
+14,430
| New | +$225K |
|
228
Pacira BioSciences
PCRX
$1.02B
| $258K | 0.09% |
6,860
-7,020
| -51% | -$282K |
|
229
iShares Russell 2000 Value ETF
IWN
$14.5B
| $248K | 0.08% |
2,000
-6,600
| -77% | -$778K |
|
|
STMP
230
DELISTED
Stamps.com, Inc.
STMP
| $245K | 0.08% |
+1,210
| New | +$222K |
|
231
Ameren
AEE
$30B
| $243K | 0.08% |
4,200
-3,050
| -42% | -$176K |
|
232
Amphastar Pharmaceuticals
AMPH
$873M
| $241K | 0.08% |
13,490
-14,033
| -51% | -$231K |
|
233
Xencor
XNCR
$1.49B
| $235K | 0.08% |
10,270
-10,693
| -51% | -$237K |
|
|
CSOD
234
DELISTED
Cornerstone OnDemand, Inc.
CSOD
| $233K | 0.08% |
5,730
-5,810
| -50% | -$215K |
|
235
Inovio Pharmaceuticals
INO
$69.6M
| $216K | 0.07% |
+2,843
| New | +$212K |
|
|
WBC
236
DELISTED
WABCO HOLDINGS INC.
WBC
| $215K | 0.07% |
+1,450
| New | +$201K |
|
|
CIVI
237
DELISTED
Civitas Solutions, Inc.
CIVI
| $212K | 0.07% |
11,500
-10,696
| -48% | -$195K |
|
|
CCXI
238
DELISTED
ChemoCentryx, Inc.
CCXI
| $208K | 0.07% |
27,988
-28,400
| -50% | -$236K |
|
239
Fluor
FLR
$6.81B
| $204K | 0.07% |
4,850
-3,530
| -42% | -$146K |
|
|
GHDX
240
DELISTED
Genomic Health, Inc.
GHDX
| $203K | 0.07% |
+6,320
| New | +$199K |
|
241
Lexicon Pharmaceuticals
LXRX
$1.05B
| $177K | 0.06% |
14,400
-15,310
| -52% | -$226K |
|
|
ASRT
242
DELISTED
Assertio
ASRT
| $95K | 0.03% |
274
-292
| -52% | -$138K |
|
243
Asbury Automotive
ABG
$3.88B
| – | – |
-18,097
| Closed | -$1.02M |
|
244
American Eagle Outfitters
AEO
$2.97B
| – | – |
-50,645
| Closed | -$610K |
|
245
Agios Pharmaceuticals
AGIO
$1.91B
| – | – |
-18,980
| Closed | -$977K |
|
|
246
Associated Banc-Corp
ASB
$5.88B
| – | – |
-102,049
| Closed | -$2.57M |
|
|
247
Avista
AVA
$3.22B
| – | – |
-64,720
| Closed | -$2.75M |
|
|
BGFV
248
DELISTED
Big 5 Sporting Goods
BGFV
| – | – |
-70,756
| Closed | -$923K |
|
249
Camden National
CAC
$992M
| – | – |
-26,462
| Closed | -$1.14M |
|
|
ELME
250
Elme Communities
ELME
$145M
| – | – |
-69,500
| Closed | -$2.22M |
|
Similar funds
WAM
GIM
PPC
MA
PC
HCG
WA
VAM
Piermont Capital Management's Q3 2017 Portfolio in Review
As of Q3 2017, Piermont Capital Management held 289 positions worth $302M, down 14% from $350M the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Piermont Capital Management withdrew a net $64.2M in Q3 2017, closing 47 positions and reducing 124 holdings. Its most notable exit was Avista, an estimated $2.75M position sold in full.
By sector, the portfolio is most concentrated in Financials at 24% of assets, up from 21% a quarter earlier, followed by Industrials and Technology.
Against the trend, Piermont Capital Management opened a new position in Dean Foods Company worth $2.45M.
- Piermont Capital Management's largest Q3 2017 buy was Dean Foods Company: 225,130 shares worth $2.45M.
- Piermont Capital Management added most to Gibraltar Industries in Q3 2017, an estimated $2.12M increase.
- Piermont Capital Management's biggest Q3 2017 reduction was Interface, cutting an estimated $2.96M.
- Piermont Capital Management fully exited Avista in Q3 2017, selling an estimated $2.75M.
- Piermont Capital Management's ten largest holdings make up 11% of its $302M portfolio in Q3 2017.
- Piermont Capital Management opened 44 new positions and closed 47 in Q3 2017.
- Piermont Capital Management's portfolio value fell 14% quarter-over-quarter to $302M.
Based on Piermont Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.